Drug-induced colitis


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

An increase in the number of people with comorbid pathology that requires the simultaneous administration of several drugs led to an increase in the frequency of drug-induced lesions of organs and systems, primarily the digestive tract. Due to the low awareness of doctors, as well as the absence of specific symptoms and markers, the diagnosis of drug-induced bowel lesions is very difficult in real clinical practice and often lasts for a long time. The main diagnostic criteria for drug-induced bowel lesions include chronological relationship with the use of a drug and the reduction or disappearance of symptoms after its withdrawal. It should be noted that it is particularly difficult to identify the drug that initiated the development of the pathological process in comorbid patients who need to take several drugs simultaneously. This review is aimed to systematization and updating of information about drug-induced bowel lesions.

Full Text

Restricted Access

About the authors

M. A Livzan

Omsk State Medical University

Omsk, Russian Federation

Olga V. Gaus

Omsk State Medical University

Email: gaus_olga@bk.ru
Cand. Sci. (Med.), Associate Professor at the Department of Faculty Therapy and Occupational Diseases Omsk, Russian Federation

N. A Nikolaev

Omsk State Medical University

Omsk, Russian Federation

References

  1. Оганов Р. Г., Симаненков В.И., Бакулин И.Г. и др. Коморбидная патология в клинической практике. Алгоритмы диагностики и лечения. Кардиоваскулярная терапия и профилактика. 2019;18(1):5-66.
  2. Grattagliano I., Ubaldi E., Portincasa P Drug-induced enterocolitis: Prevention and management in primary care. J Dig Dis. 2018;19(3):127-35. doi: 10.1111/1751-2980.12585.
  3. Philpott H.L., Nandurkar S., Lubel J., et al. Drug-induced gastrointestinal disorders. Frontline Gastroenterology. 2014;5:49-57. Doi:10.1136/ flgastro-2013-100316.
  4. Philip N.A., Ahmed N., Pitchumoni C.S. Spectrum of drug-induced chronic diarrhea. J Clin Gastroenterol. 2017;51:111-17. Doi: 10.1097/ MCG.0000000000000752.
  5. Price A.B. Pathology of drug-associated gastrointestinal disease. Br J Clin Pharmacol. 2003;56:477-82. doi: 10.1046/j.1365- 2125.2003.01980.x.
  6. Pilotto A., Franceschi M., Vitale D., et al. The prevalence of diarrhea and its association with drug use in elderly outpatients: a multicenter study. Am J Gastroenterol. 2008;103:2816-823. doi: 10.1111/j.1572-0241.2008.02107.x.
  7. Albert-Bayo M., Paracuellos I., Gonzalez-Castro A.M., et al. Intestinal Mucosal Mast Cells: Key Modulators of Barrier Function and Homeostasis. Cells. 2019;8(2):135. doi: 10.3390/cells8020135.
  8. Wells J.M., Brummer R.J., Derrien M., et al. Homeostasis of the gut barrier and potential biomarkers. Am J Physiol Gastrointest Liver Physiol. 2017;312(3):G171-G193. Doi: 10.1152/ ajpgi.00048.2015.
  9. Каратеев А.Е., Насонов Е.Л., Ивашкин В.Т. и др. Ассоциация ревматологов России, Российское общество по изучению боли, Российская гастроэнтерологическая ассоциация, Российское научное медицинское общество терапевтов, Ассоциация травматологов-ортопедов России, Российская ассоциация паллиативной медицины. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации. Научно-практическая ревматология. 2018;56 (Прил. 1):1-29
  10. Otani K., Tanigawa T., Watanabe T., et al. Microbiota Plays a Key Role in Non-Steroidal Anti-Inflammatory Drug-Induced Small Intestinal Damage. Digestion. 2017;95(1):22-8. doi: 10.1159/000452356.
  11. Гельфанд Б.Р., Проценко Д.Н., Бабаянц А.В., Каратеев А.Е. Острые кровотечения из верхних отделов желудочно-кишечного тракта: от эпидемиологии до формирования концепции консервативной терапии. Инфекции в хирургии. 2013;4:11-17.
  12. Jafar W., Jafar A.J.N., Sharma A. Upper gastrointestinal haemorrhage: an update. Frontline Gastroenterol. 2017;7(1):32-40. doi: 10.1136/flgastro-2014-100492.
  13. Ливзан М.А., Осипенко М.Ф., Лялюкова Е.А. Поражение органов пищеварения у пациентов, принимающих нестероидные противовоспалительные препараты: факторы риска, тактика ведения. Лечащий врач. 2013;7:27.
  14. Maiden L., Thjodleifsson B., Theodors A., et al. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology. 2005;128:1172-178. doi: 10.1053/j.gastro.2005.03.020.
  15. Chan F.K., Lanas A., Scheiman J., et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomized trial. Lancet. 2010;3 76:173- 79. doi: 10.1016/S0140-6736(10)60673-3.
  16. Montalto M., Gallo A., Curigliano V., et al. Clinical trial: the effects of a probiotic mixture on nonsteroidal anti-inflammatory drug enteropathy - a randomized, double-blind, cross-over, placebocontrolled study. Aliment Pharmacol Ther. 2010;32:209-14. Doi: doi: 10.1111/j.1365-2036.2010. 04324.x.
  17. Endo H., Higurashi T., Hosono K., et al. Efficacy of Lactobacillus casei treatment on small bowel injury in chronic low-dose aspirin users: a pilot randomized controlled study. J Gastroenterol. 2011;46:894-905. doi: 10.1007/s00535-011-0410-1.
  18. Ливзан М.А., Лялюкова Е.А., Костенко М.Б. Нестероидные противовоспалительные препараты: оценка рисков и пути повышения безопасности терапии. Лечащий врач. 2016;5:78.
  19. Zhao B., Sanati S., Eltorky M. Diaphragm disease: complete small bowel obstruction after long-term nonsteroidal anti-inflammatory drugs use. Ann Diagn Pathol. 2005;9:169-73. Doi: 10.1016/j. anndiagpath.2005.03.004.
  20. Ohkusa T., Terai T., Abe S. Colonic mucosal lesions associated with long-term administration of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2006;24(Suppl 4):88-95. doi: 10.1111/j.1463-1318.2009.01948.x.
  21. Hebuterne X., Dreyfus G., Fratini G., Rampal P. Nonsteroidal anti-inflammatory drug-induced colitis and misoprostrol. Dig Dis Sci. 1996;41:520-21. doi: 10.1007/bf02282331.
  22. Alsalameh S., al-Ward R., Berg P., et al. Rectal stricture associated with the long-term use of ibuprofen suppositories. Z Rheumatol. 2000;59:348-51. doi: 10.1007/s003930070058.
  23. Yamada A., Sugimoto T., Kondo S., et al. Assessment of the risk factors for colonic diverticular hemorrhage. Dis Colon Rectum. 2008;51:116-20. doi: 10.1007/s10350-007-9137-8.
  24. Ливзан М.А., Ширинская Н.В. Гастроинтестинальные осложнения у пациентов, получающих антитромботическую и антикоагулянтную терапию. Consilium Medicum. 2019;21(8):71-73.
  25. Beck K.E., Blansfield J.A., Tran K.Q., et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2006;24:2283-289. doi: 10.1200/JCO.2005.04.5716.
  26. Гаус О.В., Ливзан М.А. СРК: что мы знаем о симптомах сегодня? Consilium Medicum. 2019;21(8):42-8.
  27. Li H., He J., Jia W. The influence of gut microbiota on drug metabolism and toxicity. Expert Opin Drug Metab Toxicol. 2016;12:31-40. doi: 10.1517/17425255.2016.1121234.
  28. Balsells E., Shi T., Leese C., et al. Global burden of Clostridium Difficile infections: a systematic review and meta-analysis. J Glob Health. 2019;9(1):010407. Doi: 10.7189/ jogh.09.010407.
  29. Ливзан М.А., Кононов А.В. Клинические и фармакологические аспекты антисекреторной терапии гастроэзофагеальной рефлюксной болезни. Экспериментальная и клиническая гастроэнтеоллогия. 2004;4:55-61.
  30. Осипенко М.Ф., Скалинская М., Ливзан М.А. Вопросы безопасности ингибиторов протонной помпы. Лечащийврач. 2016;8:28.
  31. Wallace J.L., Syer S., Denou E., et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology. 2011;141:1314-322. doi: 10.1053/j.gastro.2011.06.075.
  32. Janarthanan S., Ditah I., Adler D.G., et al. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol. 2012;107:1001-1010. doi: 10.1038/ajg.2012.179.
  33. Rubio-Tapia A., Herman M.L., Ludvigsson J.S., et al. Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc. 2012;87(8):732-38. doi: 10.1016/j.mayocp.2012.06.003.
  34. Gonakoti S., Khullar S., Rajkumar A. Olmesartan Associated Enteropathy: A Rare Underdiagnosed Cause of Diarrhea and Weight Loss. Am J Case Rep. 2019;20:111-16. Doi: 10.12659/ AJCR.913207.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies